Our top pick for
Ascendis Pharma A/S is a biotechnology business based in the US. Ascendis Pharma A/S shares (ASND) are listed on the NASDAQ and all prices are listed in US Dollars. Ascendis Pharma A/S employs 482 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$119.11 - $183.98|
|50-day moving average||$133.08|
|200-day moving average||$154.67|
|Wall St. target price||$194.97|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-5.09|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||$7 million|
|Gross profit TTM||$7 million|
|Return on assets TTM||-24.95%|
|Return on equity TTM||-58.36%|
|Market capitalisation||$7.4 billion|
TTM: trailing 12 months
There are currently 3.0 million Ascendis Pharma A/S shares held short by investors – that's known as Ascendis Pharma A/S's "short interest". This figure is 2.8% up from 2.9 million last month.
There are a few different ways that this level of interest in shorting Ascendis Pharma A/S shares can be evaluated.
Ascendis Pharma A/S's "short interest ratio" (SIR) is the quantity of Ascendis Pharma A/S shares currently shorted divided by the average quantity of Ascendis Pharma A/S shares traded daily (recently around 241751.92926045). Ascendis Pharma A/S's SIR currently stands at 12.44. In other words for every 100,000 Ascendis Pharma A/S shares traded daily on the market, roughly 12440 shares are currently held short.
However Ascendis Pharma A/S's short interest can also be evaluated against the total number of Ascendis Pharma A/S shares, or, against the total number of tradable Ascendis Pharma A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ascendis Pharma A/S's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Ascendis Pharma A/S shares in existence, roughly 60 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Ascendis Pharma A/S shares, roughly 0 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Ascendis Pharma A/S.
Find out more about how you can short Ascendis Pharma A/S stock.
We're not expecting Ascendis Pharma A/S to pay a dividend over the next 12 months.
Over the last 12 months, Ascendis Pharma A/S's shares have ranged in value from as little as $119.11 up to $183.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ascendis Pharma A/S's is 0.7375. This would suggest that Ascendis Pharma A/S's shares are less volatile than average (for this exchange).
Ascendis Pharma A/S, a biopharmaceutical company, develops therapeutics for unmet medical needs. The company develops TransCon growth hormone, which completed Phase III clinical trials for growth hormone deficiency. It also develops TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for achondroplasia. In addition, the company develops preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark. .
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.